Neural repair strategies for Parkinson's disease: insights from primate models.
Level 5 - mechanism / opinion, no new human data
Narrative review of animal models and preclinical therapeutic strategies
PubMed 16719060 · doi:10.3727/000000006783982025
What was done
This review evaluates nonhuman primate models of Parkinson's disease (PD), focusing on the relative advantages and disadvantages of specific neurotoxin models, including 6-hydroxydopamine (6-OHDA), 1-methyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, paraquat, and maneb. It summarizes the application of these primate models in testing experimental therapies (trophic factor delivery, cell grafting, and deep brain stimulation) and investigating PD etiology and pathology.
What was found
The abstract reports no numerical data, effect sizes, or quantitative comparisons. It provides a qualitative overview concluding that nonhuman primate models serve as valuable translational tools for understanding disease mechanisms and advancing neurorepair and neuromodulatory therapies for PD.
Why it matters
Nonhuman primate models bridge the gap between rodent preclinical research and human clinical trials, particularly for complex neurosurgical and cell-based interventions in Parkinson's disease.
Limits
The abstract contains no primary experimental data, sample sizes, or systematic review methodology. Toxin-induced primate models do not fully replicate the chronic, progressive, and multifactorial etiology of idiopathic human Parkinson's disease.
Cited by
- context Paraquat is used experimentally in research laboratories to induce Parkinson's disease in non-human primates.